Skip to main content
Top
Published in: Thrombosis Journal 1/2016

Open Access 01-12-2016 | Research

Clinical benefit of graduated compression stockings for prevention of venous thromboembolism after total knee arthroplasty: post hoc analysis of a phase 3 clinical study of edoxaban

Authors: Takeshi Fuji, Satoru Fujita, Tetsuya Kimura, Kei Ibusuki, Kenji Abe, Shintaro Tachibana, Mashio Nakamura

Published in: Thrombosis Journal | Issue 1/2016

Login to get access

Abstract

Background

Guidelines from the Japanese Circulation Society recommend prophylaxis with anticoagulation plus intermittent pneumatic compression or graduated compression stockings (GCS) among patients at the highest risk for developing venous thromboembolism (VTE). However, the benefits of concomitant GCS use for patients undergoing total knee arthroplasty (TKA) and receiving anticoagulation remain unknown. In this study, the efficacy of GCS plus anticoagulation compared with anticoagulation alone was evaluated among patients undergoing TKA.

Methods

This study is a post hoc analysis of a previously reported phase 3 trial involving patients undergoing TKA. In the primary study, which permitted the use of GCS for mechanical prophylaxis, patients were randomized to receive edoxaban 30 mg once daily or enoxaparin 20 mg twice daily for 11 to 14 days following TKA. The primary endpoint was the incidence of VTE, a composite of symptomatic deep vein thrombosis (DVT), symptomatic pulmonary embolism (PE), and asymptomatic DVT. Treatment comparisons were performed using the chi-square test, and the 95 % confidence intervals were calculated.

Results

Among patients receiving edoxaban, the incidence of VTE was 3.8 and 5.8 % for patients with and without GCS, respectively. For patients receiving enoxaparin, VTE incidence was 8.4 and 20.8 % among those with and without GCS, respectively. Overall, VTE incidence was 6.0 and 13.0 % for anticoagulated patients with and without GCS mechanical prophylaxis, respectively. No deaths or symptomatic PE were reported during this study.

Conclusions

Although the incidence of VTE was >2-fold lower among patients receiving anticoagulation plus GCS compared with those receiving anticoagulation alone, statistical significance was not achieved. Further studies are required to confirm the findings of this preliminary analysis.

Trial registration

ClinicalTrials.gov Identifier: NCT01181102
Literature
1.
go back to reference JCS Joint Working Group. Guidelines for the diagnosis, treatment and prevention of pulmonary thromboembolism and deep vein thrombosis (JCS 2009). Circ J. 2011;75(5):1258–81.CrossRef JCS Joint Working Group. Guidelines for the diagnosis, treatment and prevention of pulmonary thromboembolism and deep vein thrombosis (JCS 2009). Circ J. 2011;75(5):1258–81.CrossRef
2.
go back to reference Anderson FA, Spencer FA. Risk factors for venous thromboembolism. Circulation. 2003;107(23 suppl 1):I-9–I-16. Anderson FA, Spencer FA. Risk factors for venous thromboembolism. Circulation. 2003;107(23 suppl 1):I-9–I-16.
4.
go back to reference Fuji T, Wang CJ, Fujita S, Kawai Y, Nakamura M, Kimura T, et al. Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial. Thromb Res. 2014;134(6):1198–204. doi:10.1016/j.thromres.2014.09.011.CrossRefPubMed Fuji T, Wang CJ, Fujita S, Kawai Y, Nakamura M, Kimura T, et al. Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial. Thromb Res. 2014;134(6):1198–204. doi:10.​1016/​j.​thromres.​2014.​09.​011.CrossRefPubMed
7.
go back to reference Clexane® for Subcutaneous Injection Kit 2000 IU. Tokyo, Japan: Sanofi-Aventis K.K; 2012 [Package Insert (Ver. 8), in Japanese]. Clexane® for Subcutaneous Injection Kit 2000 IU. Tokyo, Japan: Sanofi-Aventis K.K; 2012 [Package Insert (Ver. 8), in Japanese].
8.
go back to reference Turpie AG, Esmon C. Venous and arterial thrombosis-pathogenesis and the rationale for anticoagulation. Thromb Haemost. 2011;105(4):586.CrossRefPubMed Turpie AG, Esmon C. Venous and arterial thrombosis-pathogenesis and the rationale for anticoagulation. Thromb Haemost. 2011;105(4):586.CrossRefPubMed
10.
go back to reference Kalodiki EP, Hoppensteadt DA, Nicolaides AN, Fareed J, Gill K, Regan F, et al. Deep venous thrombosis prophylaxis with low molecular weight heparin and elastic compression in patients having total hip replacement. A randomised controlled trial. Int Angiol. 1996;15(2):162–8.PubMed Kalodiki EP, Hoppensteadt DA, Nicolaides AN, Fareed J, Gill K, Regan F, et al. Deep venous thrombosis prophylaxis with low molecular weight heparin and elastic compression in patients having total hip replacement. A randomised controlled trial. Int Angiol. 1996;15(2):162–8.PubMed
11.
go back to reference Ohlund C, Fransson SG, Starck SA. Calf compression for prevention of thromboembolism following hip surgery. Acta Orthop Scand. 1983;54(6):896–9.CrossRefPubMed Ohlund C, Fransson SG, Starck SA. Calf compression for prevention of thromboembolism following hip surgery. Acta Orthop Scand. 1983;54(6):896–9.CrossRefPubMed
Metadata
Title
Clinical benefit of graduated compression stockings for prevention of venous thromboembolism after total knee arthroplasty: post hoc analysis of a phase 3 clinical study of edoxaban
Authors
Takeshi Fuji
Satoru Fujita
Tetsuya Kimura
Kei Ibusuki
Kenji Abe
Shintaro Tachibana
Mashio Nakamura
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Thrombosis Journal / Issue 1/2016
Electronic ISSN: 1477-9560
DOI
https://doi.org/10.1186/s12959-016-0087-z

Other articles of this Issue 1/2016

Thrombosis Journal 1/2016 Go to the issue